Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Rani Therapeutics Holdings, Inc. Class A Common Stock

RANI

Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.

Last trade $0.5668
Day change +$0.0265 (+4.90%)
Day range $0.531 – $0.599
Volume 462,342
Market cap $62M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$62.36M
Price / earnings
—
Price / book
1.84×
Price / sales
9.47×
EV / sales
8.92×
EV / EBITDA
-1.71×

Profitability

Earnings per share
-$0.28
Return on assets
-61.79%
Return on equity
-95.54%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
5.26×
Quick ratio
5.26×
Cash ratio
0.39×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$23.22M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for RANI, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$1.71M$1.71M$1.71M$1.46M$0$0$172K$1.03M
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$1.71M$1.71M$1.71M$1.46M$0$0$172K$1.03M
Selling, general and administrative$4.91M$5.52M$4.89M$5.09M$4.04M$5M$5.62M$5.46M
Research and development$6.02M$5.02M$5.16M$4.91M$3.22M$5.51M$6.57M$6.81M
Total operating expenses$10.93M$10.54M$10.05M$10M$7.26M$10.51M$12.19M$15.99M
Operating income-$9.22M-$8.83M-$8.34M-$8.54M-$7.26M-$10.51M-$12.01M-$14.96M
Interest expense-$43K-$8K-$88K-$347K-$725K-$877K-$943K-$1.12M
Income before taxes-$8.81M-$8.42M-$8.02M-$9.07M-$7.91M-$11.22M-$12.74M-$15.72M
Income taxes$0$0$0$0$0$0$0$0
Net income-$8.81M-$8.42M-$8.02M-$9.07M-$7.91M-$11.22M-$12.74M-$15.72M
Net income attributable to common shareholders-$7.73M-$7.39M-$7.03M-$10.31M-$5.41M-$6.69M-$7.26M-$8.95M
EBITDA-$9.1M-$8.68M-$8.18M-$8.35M-$7.03M-$10.27M-$11.76M-$10.98M
Basic earnings per share-$0.04-$0.04-$0.04-$0.07-$0.12-$0.18-$0.22-$0.27
Diluted earnings per share-$0.04-$0.04-$0.04-$0.07-$0.12-$0.18-$0.22-$0.27

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Rani Therapeutics Holdings, Inc. Announces Pricing of $20.0 Million Registered Direct Offering of Class A Common Stock Priced At-The-Market Under Nasdaq Rules

Rani Therapeutics announced a $20 million registered direct offering of Class A common stock at $1.07 per share, along with pre-funded warrants, led by a sovereign wealth fund and other healthcare-focused investors. The offering is expected to close on May 27, 2026. The company is a clinical-stage biotherapeutics firm developing oral delivery technologies for biologics.

GlobeNewswire Inc.

Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline Prioritization

Rani Therapeutics announced the appointment of Jesper Høiland as Head of Strategy, a newly created role. Høiland, who has served as a strategic adviser since 2023, brings over 30 years of pharmaceutical leadership experience, including expertise in obesity and metabolic disease. He will be responsible for shaping corporate and pipeline strategy, prioritizing internal programs, and supporting partnering efforts. Previously, Høiland held senior positions at Ascendis Pharma, Radius Health, and Novo Nordisk.

GlobeNewswire Inc.

Rani Therapeutics to Participate in May Investor Conferences

SAN JOSE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the Company will participate in two upcoming investor conferences in May 2024. These conferences include:

GlobeNewswire Inc.

Rani Therapeutics to Present Clinical and Preclinical Data on Oral Delivery of an Ustekinumab Biosimilar via the RaniPill® Capsule at Digestive Disease Week 2024

SAN JOSE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it will present clinical and preclinical and data on the RaniPill® capsule, the company’s oral delivery platform, at Digestive Disease Week® (DDW) taking place both virtually and in-person on May 18-21, 2024 in Washington, DC.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.